만성 신부전 환자에서 빈혈치료에 대한 비타민 C의 효과

Abstract

ABSTRACT

The Effect of Intravenous Ascorbic Acid in Hemodialysis Patients

Oh, Myueng-guen Advisor : Prof. Park, Chi-young, M.D. Department of Medicine, Graduate School of Chosun University

Aims : This study was performed to investigate the effect of intravenous ascorbic acid in some hemodialysis patients with EPO-hyporesponsive anemia. Methods : The study subjects were 37 adults (18 men, 19 women) aged 30-76. The data were collected from medical records and blood tests. The patients were received 500mg of intravenous vitamin C with each dialysis session. The effects of vitamin C on EPO were assessed using paired t-test and repeated measures ANOVA. Results : The mean age was 55.5±12.3 years, and the mean duration of hemodialysis was 5.6±4.3 years. The main cause of end-stage renal disease was diabetic nephropathy. At 4 months, Hb levels significantly increased from 9.5 to 10.6 g/dL. Similarly, TSAT (30.9 to 37.4%) and vitamin C(8.2 to 24.8 mmol/L) significantly increased. EPO dose (7621.6 to 4513.0 IU/wk) significantly decreased. There are no change in ferritin, biointact parathyroid hormone levels, CRP, Aluminum, Vit B12 and Folate. Conclusions : Vitamin C can be used as an effective adjuvant therapy to EPO in hemodialysis patients. Further studies are needed to determine possible predictors of hematologic response to vitamin C.

Keywords : Anemia, Erythropoietin, Hemodialysis, Vitamin C